Matinas BioPharma Holdings Inc (MTNB) stock is up 41.56% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives MTNB stock a score of 67 out of a possible 100. That rank is mainly influenced by a fundamental score of 95. In addition to the average rating from Wall Street analysts, MTNB stock has a mean target price of $2.48. This means analysts expect the stock to rise 127.52% over the next 12 months. MTNB's rank also includes a short-term technical score of 54. The long-term technical score for MTNB is 50.
MTNB has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on MTNB!